Source study found

Story checked

Study reveals continued care delays among patients with young-onset breast cancer (opens in a new tab)

news-medical.net · 2026-10-12

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

3 supported
3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Study reveals continued care delays among patients with young-onset breast cancer

news-medical.net · 2026-10-12

The story’s checkable claims.

Read the original story

NewsLink checks it

Mixed

Every claim we could check holds up. Three of six claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

3 supported
3 not covered

Open claim evidence

The source study

Delays in breast cancer presentation, diagnosis, and treatment in young women.

Cancer · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredThe analysis also found that women who experienced delays in cancer diagnoses tended to have later stages of disease.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a subtype-specific association between presentation delay and later stage in HER2-positive luminal B tumors, but it does not report a general finding that diagnostic delays were associated with later-stage disease. This may require full-text verification.

Study evidence

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

Claim 2 of 6Not coveredPresentation delays were associated with later-stage disease in women with certain HER2-positive tumors, and those with a diagnostic delay were more likely to have late-stage disease.View evidenceHide evidence

Why this verdict

The first part is supported: presentation delays were associated with later stage in HER2-positive luminal B tumors. However, the profile does not verify the additional claim that diagnostic delay was associated with late-stage disease. At abstract depth, that part cannot be confirmed.

Study evidence

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

Claim 3 of 6Not coveredDelays were not associated with cancer-free survival or overall survival, but the authors noted that later-stage diagnosis may require more extensive treatment and affect quality of life.View evidenceHide evidence

Why this verdict

The profile supports that delays were not associated with disease-free survival/overall survival in multivariable Cox models. However, the additional statement that the authors noted later-stage diagnosis may require more extensive treatment and affect quality of life is not present in the abstract-level paper profile, so the full claim is not fully verifiable at this depth.

Study evidence

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

Study evidence

Delays (presentation, diagnostic, treatment) were not associated with disease-free survival or overall survival in multivariable Cox proportional hazards models; analyses were stratified by tumor subtype and stage.

“Multivariable Cox proportional hazards models tested the association between delays and disease-free survival (DFS) and overall survival (OS).”

Claim 4 of 6SupportedIn an analysis of adolescents and young adults with breast cancer, lower income and younger age were linked with delays in care.View evidenceHide evidence

Why this verdict

The paper profile supports that lower annual income was associated with higher odds of presentation delay and younger age was associated with higher odds of diagnostic delay. The headline uses associational wording ('linked'), which matches the observational evidence.

Study evidence

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

Claim 5 of 6SupportedIn data from 1,071 individuals in the Young Women's Breast Cancer Study, investigators identified 153 presentation delays, 120 diagnostic delays, and 228 treatment delays using prespecified time thresholds.View evidenceHide evidence

As stated153 presentation delays; 120 diagnostic delays; 228 treatment delays; 1,071 participants

Why this verdict

The profile reports the Young Women's Breast Cancer Study cohort size of 1,071 and the same delay counts: 153 presentation delays, 120 diagnostic delays, and 228 treatment delays. It also provides the prespecified thresholds: presentation ≥90 days, diagnostic ≥90 days, and treatment ≥60 days.

Study evidence

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

Study evidence

“Multivariable Cox proportional hazards models tested the association between delays and disease-free survival (DFS) and overall survival (OS).”

Claim 6 of 6SupportedAfter adjustment, lower annual income was associated with higher odds of presentation delay, while pregnancy at diagnosis, family history of breast cancer, and triple-negative breast cancer were associated with lower odds of presentation delay.View evidenceHide evidence

Why this verdict

The abstract-level findings state that lower annual income was associated with higher odds of presentation delay, while pregnancy at diagnosis, family history of breast cancer, and triple-negative subtype were associated with lower odds of presentation delay.

Study evidence

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Predictors of diagnostic delay: younger age was associated with higher odds of diagnostic delay, while triple-negative tumors were associated with lower odds.
The story reflects the younger-age association but does not mention the triple-negative association with lower odds of diagnostic delay.
From Observational cohort analysis
Treatment-delay finding: more aggressive tumor subtypes were less likely to have treatment delays.
The story reports treatment-delay counts and definitions, but not this tumor-subtype finding.
From Observational cohort analysis

7 things the story did carry across

Cohort and design: observational analysis of 1,071 women aged ≤40 with stage 0–IV breast cancer in the Young Women's Breast Cancer Study, enrolled 2006–2016.
Delay definitions: presentation delay was symptom-to-provider visit ≥90 days; diagnostic delay was presentation-to-diagnosis ≥90 days; treatment delay was diagnosis-to-treatment ≥60 days.
Delay counts: 153 presentation delays, 120 diagnostic delays, and 228 treatment delays were observed in the cohort.
Predictors of presentation delay: lower income was associated with higher odds; pregnancy at diagnosis, family history of breast cancer, and triple-negative subtype were associated with lower odds.
Stage association: in HER2-positive luminal B tumors, presentation delays were associated with later stage at diagnosis.
Survival finding: presentation, diagnostic, and treatment delays were not associated with disease-free survival or overall survival in multivariable Cox models.
Interpretive limitation: the evidence is observational and associations do not establish causation.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataIdentify patient demographic/clinical and tumor factors associated with delays in breast cancer presentation, diagnosis, and treatment among women diagnosed at age ≤40 in the Young Women’s Breast Cancer Study (2006–2016).Observational cohort analysisExpand

In plain English

In an observational analysis of 1,071 women aged ≤40 diagnosed with stage 0–IV breast cancer (Young Women’s Breast Cancer Study, 2006–2016), the authors examined predictors of three care delays—presentation (symptom→provider ≥90 days), diagnostic (presentation→diagnosis ≥90 days), and treatment (diagnosis→treatment ≥60 days)—using multivariable logistic regression with backward selection and stratified analyses by subtype and stage. Lower income was associated with greater odds of presentation delay, while pregnancy at diagnosis, family history of breast cancer, and triple‑negative subtype were associated with lower odds. Younger age was associated with higher odds of diagnostic delay; triple‑negative subtype with lower odds. More aggressive tumor subtypes were less likely to have treatment delays. In a subtype-specific analysis, presentation delays were associated with later stage in HER2‑positive luminal B tumors (p < .001). Delays were not associated with disease‑free survival or overall survival in multivariable Cox models.

Key findings

Lower annual income was associated with higher odds of presentation delay (symptom→provider ≥90 days).
Pregnancy at diagnosis, family history of breast cancer, and triple‑negative (TN) subtype were each associated with lower odds of presentation delay.

“This study included women aged ≤40 years at diagnosis of stage 0-IV BC in the Young Women's Breast Cancer Study enrolled between 2006 and 2016.”

2secondary dataAssess whether care delays (presentation/diagnostic/treatment delays) are associated with clinical outcomes (disease-free survival and overall survival), including stratification by tumor subtype and stage.Observational cohort survival analysis (multivariable Cox proportional hazards models)Expand

In plain English

In a cohort of 1,071 women aged ≤40 years with stage 0–IV breast cancer enrolled in the Young Women’s Breast Cancer Study (2006–2016), the authors used multivariable Cox proportional hazards models to test whether presentation delays (first symptom to provider visit ≥90 days), diagnostic delays (presentation to diagnosis ≥90 days), or treatment delays (diagnosis to treatment ≥60 days) were associated with disease-free survival (DFS) and overall survival (OS). Analyses were stratified by tumor subtype and stage. The abstract reports that delays were not associated with DFS or OS.

Key findings

Delays (presentation, diagnostic, treatment) were not associated with disease-free survival or overall survival in multivariable Cox proportional hazards models; analyses were stratified by tumor subtype and stage.